Exelixis Inc
Change company Symbol lookup
Select an option...
EXEL Exelixis Inc
GBCI Glacier Bancorp Inc
HEPA Hepion Pharmaceuticals Inc
MATX Matson Inc
TECK Teck Resources Ltd
BCBNF Base Carbon Inc
PAVM PAVmed Inc
HTGC Hercules Capital Inc
NRG NRG Energy Inc
NLTX Neoleukin Therapeutics Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Closing Price
$22.22
Day's Change
0.89 (4.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
22.45
Day's Low
21.56
Volume
(Heavy Day)
Volume:
4,099,941

10-day average volume:
3,148,911
4,099,941

EXEL's position in the Biotechnology industry

Industry PeersEXELAVEO

Summary

Company ProfileExelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is...
AVEO Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is focused on delivering medicines for patients with cancer. The Company’s commercial product include FOTIVDA...
Go to AVEO summary
52-Week Change

VS. INDUSTRY
-5.12%
-6.00%
Market Cap

VS. INDUSTRY
$7.1B
$226.9M
Beta

VS. INDUSTRY
0.7
0.9
Dividend Yield

VS. INDUSTRY
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
24.08x
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$1.5B
$61.3M
Profit Margin

VS. INDUSTRY
19.60%
-67.57%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
Revenue Growth (TTM)

VS. INDUSTRY
47.52%
756.67%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.